Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2023, 5(10); doi: 10.25236/FMSR.2023.051003.

Research Progress of Genome-Guided Precision Oncology Technology


Zijun Wu

Corresponding Author:
Zijun Wu

School of Physical Science, University of Chicago, Chicago, 60637, USA


As the diagnosis and treatment of diseases including cancer have entered a new era thanks to the molecular and cellular biology, especially related omics research progress since the 21st century, the so-called precision medicine that tailors diagnosis, prognosis, and treatment strategy for the actual needs of different patients based on clinicopathological features combined with molecular expression profile features has emerged. Precision medicine will change the one-size-fits-all model for groups from traditional medicine to help reduce the incidence of misdiagnosis, mistreatment, and over-treatment and improve curative effects. Genome-guided oncology refers to a new therapeutic idea for drug use based on tumor gene characteristics beyond histological disease classification and pathological classification. The relevant new drug development technology and new method of clinical trial design based on this idea provide a new thought to precision oncology. The paper summarizes the research progress of genome-guided precision oncology technology.


Genome-guided; Oncotherapy; New Technology

Cite This Paper

Zijun Wu. Research Progress of Genome-Guided Precision Oncology Technology. Frontiers in Medical Science Research (2023) Vol. 5, Issue 10: 17-22. https://doi.org/10.25236/FMSR.2023.051003.


[1] YAO H, LIANG Q, QIAN X, et al. Methodks and resourees toacess mutation-dependlent efhrcks an caneer dnug treatmmt[J]. Brief Biainfomm, 2020, 21(6):1886.

[2] PAREEK CS, SMOCZYNSKIB, TRETYN A. Sopeming tedsnalogjes and genome sequencing[J]. J Appl Gendt, 2011, 52(4):413.

[3] Huang Yurou, Wu Songfeng, Shu Kunxian, Zhu Yunping. Precision oncology from a proteogenomic perspective[J]. Journal of Biological Engineering,2022,38(10):3616-3627.DOI:10.13345/j.cjb.220528

[4] GORDON LG, WHIIE NM, EILIOTT TM, et al. Estimatingthe cods of genomie soquencing in cancer contml[J]. BMCHealth Sery Res, 2020, 20(1):492.

[5] Chen Xiang. Construction of genomic feature database and feature matching system for cancer precision medicine[D]. Zhejiang University, 2018. doi:10.27461/d.cnki.gzjdx.2018.000017. 

[6] Voigt K, Wöstemeyer J. The combination of Gilbert/ Maxam chemical sequencing and the dideoxynucleotide chain termination approach facilitates the construction of species specific PCR-primers based on diagnostic RAPD bands[J]. Microbiological research, 1995, 150(4): 373-377.

[7] Vincent A T, Derome N, Boyle B, et al. Next-generation sequencing (NGS) in the microbiological world: How to make the most of your money[J]. Journal of microbiological methods, 2017, 138: 60-71.

[8] Ye P, Luan Y, Chen K, et al. MethSMRT: an integrative database for DNA N6-methyladenine and N4-methylcytosine generated by single-molecular real-time sequencing[J]. Nucleic acids research, 2016: gkw950.

[9] Christensen K D, Dukhovny D, Siebert U, et al. Assessing the costs and cost-effectiveness of genomic sequencing[J]. Journal of personalized medicine, 2015, 5(4): 470-486.

[10] Corcoran R B, Dias-Santagata D, Bergethon K, et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation[J]. Science signaling, 2010, 3(149): ra84-ra84.

[11] Barras D, Missiaglia E, Wirapati P, et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression[J]. Clinical Cancer Research, 2017, 23(1): 104-115.

[12] Murciano-Goroff Y R, Taylor B S, Hyman D M, et al. Toward a more precise future for oncology[J]. Cancer Cell, 2020, 37(4): 431-442.

[13] Neklesa T K, Winkler J D, Crews C M. Targeted protein degradation by PROTACs[J]. Pharmacology & therapeutics, 2017, 174: 138-144.

[14] Newman, David J, Cragg G M. Natural products as sources of new drugs from 1981 to 2014[J]. Journal of natural products, 2016, 79(3): 629-661.

[15] Jiang T Y, Pan Y F, Wan Z H, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma[J]. Science Translational Medicine, 2020, 12(562): eaay0152.

[16] Krushkal J, Negi S, Yee L M, et al. Molecular genomic features associated with in vitro response of the NCI‐60 cancer cell line panel to natural products[J]. Molecular Oncology, 2021, 15(2): 381-406.

[17] Liu J, Wang L, Wang Y, et al. Design of a 30-T superconducting magnet for quantum oscillation application[J]. IEEE Transactions on Applied Superconductivity, 2019, 29(5): 1-5.